Provided by Tiger Fintech (Singapore) Pte. Ltd.

Dare Bioscience

2.04
-0.0400-1.92%
Volume:112.15K
Turnover:232.20K
Market Cap:27.50M
PE:-10.46
High:2.12
Open:2.09
Low:2.03
Close:2.08
52wk High:9.19
52wk Low:1.83
Shares:13.48M
Float Shares:13.34M
Volume Ratio:0.81
T/O Rate:0.84%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1951
EPS(LYR):-0.4770
ROE:-994.69%
ROA:-63.13%
PB:-2.16
PE(LYR):-4.28

Loading ...

Brookline Capital Markets Sticks to Their Buy Rating for Daré Bioscience (DARE)

TIPRANKS
·
Aug 19

Dare Bioscience Inc reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
Aug 15

Dare Bioscience Q2 EPS $(0.45) Beats $(0.61) Estimate

Benzinga
·
Aug 15

Daré Bioscience Inc. Reports Q2 2025 Financial Results; Cash Position Strengthened by $17.6M Capital Raise Post-Quarter-End

Reuters
·
Aug 15

Daré Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire
·
Aug 15

Dare Bioscience Inc expected to post a loss of 58 cents a share - Earnings Preview

Reuters
·
Aug 13

Dare Bioscience Inc expected to post a loss of 58 cents a share - Earnings Preview

Reuters
·
Aug 08

Daré Bioscience to Host Second Quarter 2025 Financial Results and Company Update Conference Call and Webcast on August 14, 2025

GlobeNewswire
·
Aug 07

Daré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY™ Sildenafil Cream

GlobeNewswire
·
Jul 29

Dare Bioscience Inc. Achieves Compliance with Nasdaq Listing Requirements, Faces Mandatory Panel Monitoring Until July 2026

Reuters
·
Jul 25

Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference - The Sildenafil Cream That Raises the Bar

GlobeNewswire
·
Jul 21

Why Is Daré Bioscience Stock (DARE) Up 240% Today?

TIPRANKS
·
Jul 15

Top Midday Gainers

MT Newswires Live
·
Jul 15

Crude Oil Moves Lower; Daré Bioscience Shares Jump

Benzinga
·
Jul 15

BUZZ-Daré Bioscience soars on birth control device trial data

Reuters
·
Jul 14

Dare reports interim safety, efficacy results from Phase 3 trial of Ovaprene

TIPRANKS
·
Jul 14

Daré Bioscience Announces Positive Interim Phase 3 Results for Hormone-Free Contraceptive Ovaprene®

Reuters
·
Jul 14

Dare Bioscience receives $6M non-dilutive grant installment

TIPRANKS
·
Jul 11

Daré Bioscience Receives $6 Million Non-Dilutive Grant Installment; $37.8M to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Disorders

GlobeNewswire
·
Jul 11

Dare Bioscience Inc. Held Shareholder Meeting to Vote on Key Proposals

Reuters
·
Jul 10